北京商报讯（记者 刘宇阳 实习生 姚榕琰）2月11日，广东证监局发布公告称，经查，珠海鼎华股权投资管理有限公司（以下简称"珠海鼎 华股权投资"）存在管理的佛山市鼎华壹号股权投资合伙企业（有限合伙）（以下简称"鼎华壹号"）未按照合伙协议约定进行投资运作；未 按照鼎华壹号合伙协议约定向投资者披露定期报告的问题。 广东证监局指出，上述行为违反了相关规定，决定对珠海鼎华股权投资采取责令改正的行政监管措施，要求其高度重视，采取切实有效的 措施进行整改，对相关责任人员进行问责。 ...

Core Viewpoint - Anhui Securities Regulatory Bureau announced that Zhongding Asset Management Co., Ltd. has violated regulations in its private equity fund operations, leading to the issuance of a warning letter and recording in the integrity archive of the securities and futures market [1]. Group 1: Regulatory Violations - Zhongding Asset Management failed to report changes in actual controllers to the China Securities Investment Fund Industry Association [1]. - The company exhibited deficiencies in corporate governance and internal controls [1]. - There were delays in handling profit distribution matters for some managed funds [1]. - The firm did not fulfill its information disclosure obligations in a timely manner [1]. - Zhongding Asset Management failed to complete the filing procedures for certain funds promptly [1].

Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

北京商报讯（记者 和岳）2月11日，国家广播电视总局办公厅、商务部办公厅发布关于开展餐饮老字号 短视频宣传活动的通知，活动时间为今年2月（自通知印发之日起）至3月3日。其中提出，各地广播电 视、商务主管部门指导广播电视媒体创作推出一批特色鲜明、传播广泛的短视频。创新表达方式，聚焦 各地餐饮老字号历史故事、技艺传承、美食风味，突出餐饮老字号企业打造的年夜饭套餐、新春团圆宴 等消费场景，以观众喜闻乐见的网感语言、叙事方式讲好老字号的新时代故事，吸引更多群众走进老字 号、寻味中国年，推动老字号餐饮消费。 ...

Core Insights - NetEase Youdao reported a total net revenue of 5.91 billion yuan for the year 2025, marking a year-on-year growth of 5% [1] - The company achieved an operating profit of 220 million yuan, which represents a significant increase of 48.7% year-on-year [1] - For the first time, NetEase Youdao realized a full-year operating cash inflow of 55.2 million yuan, successfully meeting its financial goals set at the beginning of the year [1] Quarterly Performance - In Q4 2025, NetEase Youdao continued its steady profitability with a net revenue of 1.56 billion yuan, reflecting a year-on-year growth of 16.8% [1] - The operating profit for the quarter was 60.2 million yuan, primarily driven by strategic investments in high-growth areas such as Youdao Lingxi and advertising [1] - The operating cash inflow for the quarter reached 180 million yuan, showing a year-on-year increase of 16.4% [1] Learning Services Segment - In Q4 2025, the net revenue from learning services amounted to 730 million yuan, which is a year-on-year growth of 17.7%, indicating a return to growth after business adjustments [1] - Youdao Lingxi, as a core growth engine, saw its net revenue increase by over 40% year-on-year, achieving both scale and reputation breakthroughs [1] - Following the launch of the Chinese AI essay correction tool, the company announced the upcoming release of an English AI essay correction tool supported by the "Ziyue" large model [1]

北京商报讯（记者 王寅浩 宋雨盈）2月11日，恒瑞医药发布公告称，公司子公司苏州盛迪亚生物医药有 限公司的注射用瑞康曲妥珠单抗（SHR-A1811）被国家药品监督管理局药品审评中心纳入突破性治疗品 种名单，这是瑞康曲妥珠单抗第10项获得突破性治疗认证的适应症。 公告显示，恒瑞医药注射用瑞康曲妥珠单抗已于2025年5月在国内获批上市，适用于治疗存在HER2激活 突变且既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌成人患者。 ...

Core Viewpoint - The company, Anglikang, has announced its participation in the national organized procurement for the continuation of products whose agreements from batches 1-8 have expired, with several products expected to be selected for procurement [1] Group 1: Selected Products - The products proposed for selection include: - Amlodipine Besylate Tablets - Amlodipine Tablets - Aluminum Magnesium Chewable Tablets - Cefalexin Capsules - Cephalexin Capsules - Paliperidone Succinate Tablets - Ticagrelor Tablets - Theophylline Injection - Pregabalin Capsules - Levofloxacin Tablets - Cefuroxime Axetil Capsules - L-Carnitine Injection [1] Group 2: Procurement Details - The continuation procurement is based on the demand reported by medical institutions for each company's products, with the purchasing volume determined according to the selected price gradient [1] - The procurement period will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable penicillin sodium, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is approved in a dosage of 0.96g (1.6 million units) [1] - This medication is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1]

兰石重装表示，王炳正除担任公司副总经理外，还兼任子公司兰州兰石超合金新材料有限公司党委书 记、董事。目前，公司对王炳正负责的相关工作已进行了妥善安排。截至公告披露日，公司董事及其他 高级管理人员均正常履职，公司董事会及管理层依法运作，公司生产经营情况正常，没有受到影响。 北京商报讯（记者 王蔓蕾）2月11日晚间，兰石重装（603169）披露公告称，公司于近日收到静宁县监 察委员会签发的《立案通知书》和《留置通知书》，公司副总经理王炳正因涉嫌违纪和职务违法犯罪问 题被立案调查和实施留置措施。 ...

天际股份表示，目前，公司各项生产经营活动均正常开展，上述事项不会对公司的正常生产经营活动产 生重大影响。立案调查期间，公司将积极配合证监会的各项工作，严格按照相关规定及监管要求履行信 息披露义务。 北京商报讯（记者 马换换 李佳雪）2月11日晚间，天际股份（002759）披露公告称，公司于当日收到证 监会下发的《立案告知书》，因公司涉嫌信息披露违法违规，证监会决定对公司立案。 ...